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Background: The paracaspase mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is
crucial for lymphocyte activation through signaling to the transcription factor NF-κB. Besides functioning as a
scaffold signaling protein, MALT1 also acts as a cysteine protease that specifically cleaves a number of substrates
and contributes to specific T cell receptor-induced gene expression. Recently, small molecule inhibitors of MALT1
proteolytic activity were identified and shown to have promising anticancer properties in subtypes of B cell
lymphoma. However, information on the therapeutic potential of small compound inhibitors that target MALT1
protease activity in autoimmunity is still lacking.
Methods: The present study aimed to elucidate whether MALT1 protease inhibitors are also useful in the treatment
of lymphocyte-mediated autoimmune pathologies such as multiple sclerosis (MS). For this, we studied the therapeutic
potential of a recently identified inhibitor of MALT1 protease activity, the phenothiazine derivative mepazine, in the
context of experimental autoimmune encephalomyelitis (EAE), the main animal model for MS.
Results: We demonstrate that administration of mepazine prophylactically or after disease onset, can attenuate EAE.
Importantly, while complete absence of MALT1 affects the differentiation of regulatory T (Treg) cells in vivo, the MALT1
protease inhibitor mepazine did not affect Treg development.
Conclusions: Altogether, these data indicate that small molecule inhibitors of MALT1 not only hold great promise for
the treatment of B cell lymphomas but also for autoimmune disorders such as MS.
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Multiple sclerosis (MS) is the most common chronic in-
flammatory demyelinating disease of the central nervous
system (CNS) [1]. MS and experimental autoimmune en-
cephalomyelitis (EAE), its main animal model, are charac-
terized by myelin-specific autoreactive T cells, which home
to the CNS where they initiate a vicious cycle of
inflammation and tissue damage, eventually leading to
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unless otherwise stated.demyelination and degeneration [2]. The transcription
factor NF-κB plays a central role in T cell activation and
proliferation. Upon stimulation of the T cell receptor
(TCR), protein kinase C θ-mediated phosphorylation of
CARMA1 results in the recruitment of the scaffolding
proteins Bcl-10 and MALT1, forming the so-called
CBM complex, which mediates the recruitment of the
E3 ubiquitin ligase TRAF6 and other downstream sig-
naling molecules that are essential for the activation of
the IκB kinase (IKK) complex. Next to its scaffold func-
tion, MALT1 has recently been shown to also have
enzymatic activity [3-7]. In contrast to MALT1’s scaf-
folding function, its protease activity is not crucial for
IKK activation [8], but supports specific TCR-induced
gene expression by inactivating negative regulators suchal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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family member RelB [4], and the RNase Regnase-1 [7].
At the cellular level, MALT1 proteolytic activity has
been implicated in MALT lymphoma and activated B
cell-like diffuse large B cell lymphoma (ABC-DLBCL)
[3,9-11]. In this context, treatment of ABC-DLBCL cells
with the MALT1 protease peptide inhibitor z-VRPR-fmk
reduces constitutive NF-κB activity and cell proliferation
[12,13]. Recently, small molecule MALT1 protease inhibi-
tors also were described and shown to suppress prolifera-
tion of ABC-DLBCL in vitro and in xenotransplanted
tumors in vivo [14,15], positioning MALT1 as an attractive
anticancer drug target. The phenothiazine derivative
mepazine was shown to act as a potent noncompetitive
MALT1 inhibitor by binding to an allosteric pocket on
MALT1 [16]. The reversible mode of action and effective-
ness of MALT1 inhibition by mepazine in vivo [15] indi-
cates a possible clinical use also for the treatment of
severe autoimmune diseases. Therefore, we here assessed
the potential of mepazine on the development and pro-
gression of EAE. We demonstrate significant protective
activities of mepazine when administered either early (be-
fore the onset of acute disease) or late (at the peak of dis-
ease), illustrating that MALT1 is not only an attractive
drug target in cancer but also in autoimmunity.
Methods
Mice
Male mice aged 8 to 10 weeks old were purchased from
Janvier N.V. and kept in an specific pathogen free (SPF)
animal facility in individually ventilated cages. Food and
water was provided ad libitum for the duration of the
experiments. All animal experiments were performed ac-
cording to institutional, national and European guidelines
and were approved by the Gent University institutional re-
view committee.
Experimental autoimmune encephalomyelitis induction
and follow-up
EAE was induced as previously described [17]. Briefly,
mice were subcutaneously immunized with an emulsion
of 200 μg myelin oligodendrocyte glycoprotein peptide
(MOG35-55) peptide (Charite, Institute for Medical
Immunology, Berlin, Germany) and complete Freund’s ad-
juvant (Sigma-Aldrich, St. Louis, MO, USA) supplemented
with 10 mg/ml Mycobacterium Tuberculosis H37RA
(BD Bioscience, San Diego, CA, USA). On the day of
immunization and 48 hours after, mice also received 50
ng of pertussis toxin (Sigma-Aldrich, St. Louis, MO,
USA) in sterile PBS intraperitoneally (i.p.). For passive
induction of EAE, spleens from immunized mice were
isolated 10 days post-immunization. Splenocytes were
cultured in RPMI 1640 supplemented with 10% FBS, so-
dium pyruvate, L-glutamine, nonessential amino acids,antibiotics, 30 μM MOG35-55 peptide and 10 ng/ml re-
combinant mouse IL-23 (eBioscience, San Diego, CA,
USA). After 48 hours, splenocytes were harvested,
washed and resuspended in PBS. A total of 3 × 107 cells
were injected intravenously (i.v.) into recipient mice,
which were sub-lethally irradiated (400 cGy) 24 hours
prior to cell transfer. Mice received 200 ng pertussis
toxin i.p. on the day of cell transfer and 48 hours later.
Body weight and clinical disease development were
followed up daily. Paralysis was scored according to a
scale as follows: 0, normal; 1, weakness of tail; 2, complete
loss of tail tonicity; 3, partial hind limb paralysis; 4,
complete hind limb paralysis; 5, forelimb paralysis or
moribund; and 6, death. Intermediate scores of 0.5 were
given when necessary. To eliminate any diagnostic bias,
mice were scored blindly.
Treatment with mepazine
Mice were randomly treated with either mepazine or con-
trol solution to eliminate possible cage effects. Mepazine
acetate (Chembridge, San Diego, CA, USA) was solubi-
lized in 0.7 × PBS at a concentration of 2 mg/ml. Mice
were injected i.p. twice daily with 8 mg/kg starting at day
7 post-immunization, or between days 14 and 17 when
they reached a clinical score of 2. For adoptive transfer
EAE, donor mice were injected with mepazine or vehicle
from the day of immunization until the isolation of
splenocytes.
Histological analysis
Mice were transcardially perfused with PBS containing 5
IU/ml heparin (De Pannemaeker N.V., Gent, Belgium)
followed by perfusion with 4% paraformaldehyde. Spinal
cords were dissected, dehydrated and embedded in par-
affin blocks. Sections of 2 μm were stained with
hematoxylin and eosin (H & E), Luxol fast blue (LFB)
(Solvent Blue 38, practical grade, Sigma Genosys, The
Woodlands, TX, USA) for assessment of demyelination,
and antibodies against CD3 (Clone CD3-12, Serotec,
Raleigh, NC, USA), Mac-3 (Clone CD107b, M3/84, BD
Biosciences, San Diego, CA, USA), B220 (Clone RA3-
6B2, BD Biosciences, San Diego, CA, USA) or amyloid
precursor protein (APP) (Clone 22C11, Millipore, Darmstadt,
Germany). Sections were rehydrated and incubated in
10 mM citrate buffer for 5 minutes at 94°C. Nonspecific
binding was blocked by incubating sections in 0.1 M
PBS containing 10% FCS and 1% Triton x-100 for 30
minutes. Primary antibodies were incubated overnight
at 4°C. Histological quantification was described previ-
ously [18].
Cytokine analysis and quantitative real-time PCR
Total RNA was isolated using TRIzol reagent (Invitro-
gen) and Aurum Total RNA Isolation Mini Kit (Bio-Rad
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turer’s instructions. Synthesis of cDNA was performed
using iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s in-
structions. A total of 10 ng of cDNA was used for quanti-
tative PCR in a total volume of 10 μl with SensiFast SYBR
No-Rox Kit (GeC Biotech, London, UK) and specific
primers on a LightCycler 480 (Roche). Real-time PCR
reactions were performed in triplicates. The following
mouse-specific primers were used: hprt forward, 5’-
AGTGTTGGATACAGGCCAGAC-3’; hprt reverse, 5’-CC
GTGATTCAAATCCCTGAAGT-3’; gapdh forward, 5’-T
GAAGCAGGCATCTGAGGG-3’; gapdh reverse, 5’-CGA
AGGTGGAAGAGTGGGAG-3’; IFNγ forward, 5’-GCCA
AGCGGCTGACTGA-3’; IFNγ reverse, 5’-TCAGTGAAG
TAAAGGTACAAGCTACAATCT-3’; IL-2 forward, 5’-G
TGCCAATTCGATGATGAGTCA-3’; IL-2 reverse, 5’-G
GGCTTGTTGAGATGATGCTTT-3’; tbet forward, 5’-
AGAACGCAGAGATCACTCAG-3’; tbet reverse, 5’- GG
ATACTGGTTGGATAGAAGAGG-3’; IL-13 forward, 5’-
TCAGCCATGAAATAACTTATTGTTTTGT-3’; IL-13
reverse, 5’-CCTTGAGTGTAACAGGCCATTCT-3’; STA
T6 forward, 5’-GGGTGTTAATGCTCGAATGTGATA-3’;
STAT6 reverse 5’-CACAATGTCTCTATGTTTCTG TAT
GTTGAG-3’; GATA3 forward, 5’-GGCAGAAAGCAAAA
TGTTTGCT-3’; GATA3 reverse, 5’-TGAGTCTGAATGG
CTTATTCACAAAT-3’; IL-6 forward, 5’-GAGGATACCA
CTCCCAACAGACC-3’; IL-6 reverse, 5’-AAGTGCATCA
TCGTTGTTCATACA-3’; RORγt forward, 5’-TGTCCTG
GGCTACCCTACT-3’; RORγt reverse, 5’-GCACCCCT
CACAGGTGATAA-3’; IL-17A forward, 5’-CAGGACGC
GCAAACATGA-3’; IL-17A reverse, 5’-GCAACAGCAT
CAGAGACACAGAT-3’; Foxp3 forward, 5’-TTCCTTCC
CAGAGTTCTTCC-3’; Foxp3 reverse, 5’-CTCAAATT
CATCTACGGTCCAC -3’; IL-10 forward, 5’-GGTGTCC
TTTCAATTGCTCTCAT -3’; IL-10 reverse, 5’-TCACAA
CTCTCTTAGGAGCTCTGAACT -3’; TGFβ forward, 5’-
GCTGAACCAAGGAGACGGAATA -3’ and TGFβ re-
verse, 5’-GAGTTTGTTATCTTTGCTGTCACAAGA -3’.T cell recall assay
T cell recall responses were assessed in splenocytes iso-
lated from 10 d post-immunization with MOG35-55 pep-
tide. Erythrocytes were lysed using ACK lysis buffer and
splenocytes were cultured in flat-bottomed 96-well
plates at a density of 7 × 105 cells/well in DMEM sup-
plemented with 5% FCS, L-glutamine, nonessential
amino acids and antibiotics. Cells were pretreated with
13 μM mepazine for 1 hour, after which 1, 10 or 30 μg/
ml MOG35-55 peptide was added. After 48 hours, super-
natant was collected and concentrations of IL-2, IFNγ
and IL-17 were determined by ELISA (eBioscience, San
Diego, CA, USA).Cell culture and immunoblot
CD4+ T cells were purified from naïve mice using the CD4+
T cell isolation kit (Miltenyi Biotech, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. T
cells were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum, L-glutamine, sodium pyruvate, non-
essential amino acids and antibiotics. Jurkat cells were cul-
tured as described before [6]. Cells were pretreated with
mepazine, after which they were stimulated with 200
ng/ml PMA (Sigma-Aldrich, , St. Louis, MO, USA) and 1
μM ionomycin (Calbiochem, Darmstadt, Germany) in the
presence or absence of mepazine for indicated time points.
After stimulation, cells were lysed in 50 mM Hepes, pH
7.6, 250 mM NaCl, 5 mM EDTA, 0.5% NP-40 and phos-
phatase and protease inhibitors. Proteins were separated by
SDS-PAGE and analyzed by semi-dry immunoblotting and
detection via enhanced chemiluminescence (Perkin-Elmer
Life Sciences, Waltham, MA, USA). Antibodies that were
used are anti-A20 (clone 59A426, eBioscience, San Diego,
CA, USA), anti-CYLD (E10, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA), anti-MALT1 (B-12, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-
BCL10 (EP 606Y, Abcam Inc., Cambridge, MA, USA),
anti-P-p38 (#9215, Cell Signaling, Danvers, MA, USA),
anti-p38 (#9212, Cell Signaling, Danvers, MA, USA), anti-
P-IκBα (#9246, Cell Signaling, Danvers, MA, USA), anti-
IκBα (sc-371, Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA), anti-P-ERK (#9101, Cell Signaling, Danvers,
MA, USA), anti-ERK (#9102, Cell Signaling, Danvers, MA,
USA), anti-P-JNK (#9251, Cell Signaling, Danvers, MA,
USA), anti-JNK (sc-571, Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA) and anti-actin (MP 6472 J, MP
Biochemicals, Santa Ana, CA, USA).
In vitro regulatory T cell differentiation
CD4+ T cells were purified from naïve mice using the
CD4+ T cell isolation kit (Miltenyi Biotech, Bergisch
Gladbach, Germany) according to the manufacturer’s in-
structions. Regulatory T cells were depleted using the
CD25 MicroBead kit (Miltenyi Biotech, Bergisch Gladbach,
Germany) according to the manufacturer’s instructions.
Purified CD4+ CD25- T cells were cultured in IMDM sup-
plemented with 5% fetal bovine serum, glutamax, sodium
pyruvate, non-essential amino acids and antibiotics in 48-
well plates at a density of 0.5 × 106 cells per well. Wells
were pre-coated with 5 μg/ml anti-CD3 (clone 145-2C11,
BD Biosciences, San Diego, CA, USA) at 37°C for 4 hours
and rinsed twice with PBS before applying cells. To induce
regulatory T cell differentiation, cells were stimulated
with 1 μg/ml anti-CD28 (clone 37.51, BD Biosciences,
San Diego, CA), 10 ng/ml hTGFβ (R&D Systems,
Minneapolis, MN, USA), 10 μg/ml anti-IFNγ (clone
XMG1.2, eBioscience, San Diego, CA, USA) and 10 μg/ml
anti-IL-4 (clone 11B11, BD Biosciences, San Diego, CA,
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of 5 μM or 10 μM. Cells were analyzed for Foxp3 expres-
sion at day 3 and day 5 in culture.Flow cytometry
Blood was collected from vehicle and mepazine treated
mice at different time points. Red blood cells were re-
moved by two steps of ACK (Lonza, Basel, Switzerland)
treatment. Cells were stained with Aqua Live/Dead (Life
Technologies), anti-CD16/32 (clone 2.4G2, Fc Block; BD
Biosciences, San Diego, CA, USA), anti-CD3-eFluor 450
(clone 145-2C11; eBioscience, San Diego, CA, USA),
anti-CD4-FITC (clone GK1.5, BD Biosciences, San Diego,
CA, USA), anti-CD25-allophycocyanin-Cy7 (clone PC61;
BD Biosciences, San Diego, CA, USA) for 30 minutes at
4°C in PBS supplemented with 0.1% bovine serum albumin
(Sigma) and 2 mM EDTA. Prior to staining with anti-
Foxp3-PE or anit-Foxp3-APC (clone FJK-16 s), cells were
fixed and permeabilized using the Anti-Mouse/Rat Foxp3
Staining Set PE (eBioscience, San Diego, CA, USA) accord-
ing to the manufacturer’s instructions. Measurements were
performed on a BD LSR II cytometer (BD Biosciences, SanFigure 1 Treatment with mepazine reduces experimental autoimmun
treated with 8 mg/kg mepazine (n = 14) or vehicle (n = 16) starting at day
8 mg/kg mepazine (n = 14) or vehicle (n = 16) starting at day 7 post-immu
from MOG35-55- immunized, vehicle-treated (n = 5) or mepazine-treated (n
splenocytes from MOG35-55-immunized, vehicle-treated (n = 5) or mepazine
experiments and depicted as mean ± SEM *P <0.05.Diego, CA, USA) and data were analyzed using FlowJo
software (Tree Star).
Statistical analysis
Results are presented as mean ± SEM. Differences be-
tween two groups were assessed using a two-tailed Stu-
dent t test or one-way ANOVA. Differences in remission
were analyzed using a Gehan-Breslow-Wilcoxon test.
Differences were considered significant when P <0.05.
Results
Mepazine treatment attenuates experimental
autoimmune encephalomyelitis induction
In order to determine the therapeutic potential of mepa-
zine in EAE, C57BL/6 mice were immunized with
MOG35-55 peptide and were administered mepazine or
vehicle twice daily from day 7 post-immunization on-
ward. Disease progression was evaluated by assessment
of clinical scoring and body weight. All vehicle-treated
mice developed EAE, following a typical EAE course
with onset at approximately day 16 and reaching a max-
imal clinical score of 3.8 (Figure 1A, Table 1). In con-
trast, when mice were administered mepazine, diseasee encephalomyelitis (EAE) severity. (A) Disease progression of mice
7 post-immunization. (B) Percentage body weight of mice treated with
nization. (C) Disease progression of naïve mice receiving splenocytes
= 5) mice. (D) Percentage body weight of naïve mice receiving
-treated (n = 5) mice. Data are obtained from two independent
Table 1 Clinical features of MOG35-55-immunized mice
treated with mepazine or vehicle
Treatment Incidence Day of
disease onseta
Mean maximal
clinical scorea
Vehicle 100% (8/8) 16.6 ± 0.9 3.8 ± 0.3
Mepazine 33% (3/10) 16.3 ± 1.3 2.1 ± 0.4b
aResults are displayed as mean ± SEM.
bP <0.01.
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significantly reduced, with mice reaching a maximal clin-
ical score of 2.1 (Figure 1A, Table 1). In addition, whereas
vehicle-treated mice lost substantial body weight during
EAE, reflecting disease progression, this loss was signifi-
cantly reduced in mepazine-treated mice (Figure 1B). To
determine whether this attenuated EAE was the result of
mepazine on the peripheral immune compartment, an
adoptive-transfer EAE experiment was performed. Spleno-
cytes from mice immunized with MOG35-55 and treated
with vehicle or mepazine were re-stimulated in vitro with
MOG35-55 peptide and IL-23, after which they were trans-
ferred to naïve mice that were irradiated 1 day prior to cell
transfer. Recipient mice receiving cells from vehicle
treated mice all developed EAE, with an onset at day 21
and a mean maximal clinical score of 4.4 (Figure 1C,
Table 2). In contrast, in recipient mice receiving spleno-
cytes from mepazine-treated mice, disease incidence was
reduced to 60%. In addition, the maximal clinical score
was reduced to 2.5, suggesting a milder disease progres-
sion. Finally, the loss in body weight was also noticeably
reduced in recipient mice receiving splenocytes from
mepazine-treated donor mice, compared to those receiv-
ing splenocytes from vehicle-treated mice (Figure 1D).
These results suggest that mepazine alters the auto-
reactive peripheral immune response, resulting in a milder
EAE induction and progression.
Mepazine treatment reduces central nervous system
inflammation
To characterize the milder disease course in mepazine-
treated mice, histopathological analysis was performed on
spinal cord sections of vehicle- and mepazine-treated mice
at day 24 post-immunization. Typically for EAE pathology,
vehicle-treated mice demonstrated severe spinal cord de-
myelination and axonal degeneration, visualized by LFB
staining and APP+ depositions, respectively (Figure 2A).Table 2 Clinical features of mice receiving donor
cells from MOG35-55-immunized, vehicle-treated or
mepazine-treated mice
Donor cells Incidence Day of
disease onset
Mean maximal
clinical score
Vehicle 100% (5/5) 21.0 ± 1.5 4.4 ± 0.3
Mepazine 60% (3/5) 17.7 ± 1.3 2.5 ± 0.7In addition, inflammatory infiltration of CD3+ T cells and
Mac-3+ macrophages was present in spinal cords of
vehicle-treated mice (Figure 2B). In contrast, mepazine-
treated mice demonstrated reduced spinal pathology and
inflammation (Figure 2A, B, Table 3). Next, we determined
the expression of Th1, Th2, Th17 and Treg factors in
spinal cord tissue of recipient mice receiving cells from
vehicle- or mepazine-treated animals. While most of these
factors were clearly increased in vehicle-treated mice dur-
ing EAE, their expression was suppressed in mepazine-
treated conditions (Figure 2C-F). These results demon-
strate that mepazine protects mice from EAE pathology
by reducing the influx of inflammatory cells, thus attenu-
ating tissue damage in the spinal cord.
Mepazine abolishes peripheral autoreactive T cell
activation
Previously, it has been demonstrated that mepazine in-
hibits T cell activation in vitro, likely by acting as an in-
hibitor of MALT1 protease activity [15]. Similarly, we
found that mepazine inhibited the proteolytic processing
of A20, BCL-10 and CYLD in PMA/ionomycin stimu-
lated Jurkat T cells (Figure 3A). Furthermore, mepazine
strongly inhibited TCR-induced JNK phosphorylation,
both in Jurkat cells as in primary T cells (Figure 3B-C).
Additionally, a minor delay in TCR-induced NF-κB acti-
vation could be shown in Jurkat cells as evidenced by a
slightly delayed IκBα phosphorylation and degradation
(Figure 3B). To test whether mepazine could also inhibit
the activation of autoreactive MOG35-55-specific T cells,
a T cell recall experiment was performed. Splenocytes
from MOG35-55-immunized mice were harvested at day
10 post-immunization and re-stimulated with their auto-
antigen in the presence or absence of mepazine, after
which activation of autoreactive T cells was assessed by
means of cytokine release in the culture medium. As ex-
pected, cells re-stimulated in vitro with MOG35-55 pep-
tide produced IL-2, IFNγ and IL-17 (Figure 4). In sharp
contrast however, the addition of mepazine completely
suppressed the production of these cytokines. These
results suggest that the protective phenotype of mepazine-
treated mice may be due to a reduced activation of auto-
antigen specific T cells (Figure 4).
Mepazine treatment does not affect peripheral regulatory
T cells
Mice lacking MALT1 have a severely reduced population
of regulatory T cells (Tregs) [17]. To investigate whether
treatment with mepazine would have an impact on Treg
numbers, splenocytes from MOG35-55-immunized and
mepazine- or vehicle-treated mice were analyzed at day
24 post-immunization. As previously shown, CD3+ CD4+
Foxp3+ Tregs were largely absent in MALT1 knockouts
when compared to control mice; however, the percentage
AB
Vehicle Mepazine
LF
B
-
PA
S
A
PP
Vehicle Mepazine
CD
3
M
ac
-
3
C
D
E
F
Figure 2 Reduced central nervous system demyelination, axonal damage and inflammatory cell infiltration and cytokine expression
in mepazine-treated mice. Histopathology on spinal cords of vehicle-treated (n = 5) or mepazine-treated (n = 6) mice. (A) Demyelination
(blue) and axon damage (APP, brown) were assessed. (B) Stainings for infiltrating T cells (CD3, brown) and macrophages (Mac-3, brown) by
immunohistochemistry. Scale bars, 500 μm (top panel), 200 μm (lower panel). Expression of Th1 (C), Th2 (D), Th17 (E) and Treg-linked (F)
factors in spinal cord of acceptor mice receiving splenocytes from vehicle- or mepazine-treated mice, 28 days post-splenocyte transfer. Data
are depicted as mean ± SEM *P <0.05.
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reduced compared to control mice, nor did it differ be-
tween vehicle- or mepazine-treated animals (Figure 5A).
To rule out an effect of mepazine on Treg numbers dur-
ing the induction phase of EAE, blood was collected at
different time points post-immunization and analyzed for
Foxp3 expressing T cells. We show that the percentage of
Tregs did not differ between vehicle- and mepazine-
treated mice (Figure 5B). Finally, the influence of mepa-
zine on Treg differentiation in vitro was analyzed, but no
effect of mepazine on the capacity of naïve T cells to dif-
ferentiate into Tregs could be demonstrated (Figure 5C).These results clearly show that mepazine does not influ-
ence the Treg population during EAE induction and
progression.
Mepazine suppresses experimental autoimmune
encephalomyelitis progression
The above mentioned results suggest that mepazine
treatment inhibits EAE by preventing the activation of
MOG35-55-specific autoreactive T cells. To determine
whether mepazine could also be used in a therapeutic
setting, we performed an experiment in which mepazine
was administered in diseased mice the moment they
Table 3 Quantification of spinal cord cell infiltration, demyelination and axonal damage
Treatment Demyelination (%)a APP+/mm2a CD3+/mm2a Mac-3+/mm2a
Vehicle 32.9 ± 6.0 45.4 ± 5.5 114.2 ± 59.2 480.8 ± 191.9
Mepazine 17.6 ± 7.5 29.2 ± 12.9 50.3 ± 22.5 246.5 ± 113.6
Samples were obtained from vehicle (n = 5) or mepazine (n = 6) treated animals. aResults are displayed as mean ± SEM.
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gression was also attenuated under these conditions in
mepazine-treated mice when compared to control mice
(Figure 6A). In addition, while approximately 40% of
vehicle-treated mice went into remission, defined as a
clinical score of ≤1.5, this percentage was significantly
increased to 80% in mepazine-treated mice (Figure 6B).
Together, these results demonstrate that in addition to
attenuating the induction of EAE, mepazine can also
suppress the progression of the disease.
Discussion
Recently, the phenothiazine derivative mepazine has
been demonstrated to be a potent inhibitor of MALT1
protease activity in ABC-DLBCL and primary T cells.
More specifically, mepazine inhibited TCR-induced IL-2
production and proteolytic processing of the MALT1
substrate RelB in primary T cells [15]. In line with this,
we found that mepazine prevented the processing of
other MALT1 substrates, CYLD, BCL-10 and A20, in
primary T cells and Jurkat T cells upon TCR signaling.Figure 3 Mepazine inhibits MALT1 substrate cleavage and reduces N
purified primary CD4+ T cells were stimulated with PMA plus ionomycin fo
minutes prior to stimulation. Cleavage of MALT1 substrates CYLD, A20 and
for IκBα, phospho-IκBα, JNK, phospho-JNK, p38, phospho-p38, ERK, phosphIn addition, mepazine significantly inhibited TCR-induced
JNK phosphorylation, consistent with the previously de-
scribed requirement for MALT1 and MALT1-mediated
processing of CYLD for TCR-induced JNK signaling
[6]. TCR-induced phosphorylation of p38 and ERK
MAP kinases, as well as IκBα phosphorylation, degrad-
ation and re-synthesis, were only slightly delayed in
mepazine-treated Jurkat cells and not affected in pri-
mary T cells, consistent with previous reports showing
that MALT1 proteolytic activity is largely dispensable
for these events [8].
Given the ability of mepazine to inhibit MALT1 para-
caspase activity and TCR-induced signaling, we sought
to investigate the in vivo therapeutic effect of mepazine
during EAE, which is characterized by a T-cell
dependent autoimmune response against MOG35-55.
Mice treated with mepazine prophylactically, before dis-
ease symptoms are apparent, are clearly protected in
EAE, as shown by a significant reduction in clinical dis-
ease symptoms and histopathological parameters such as
spinal cord demyelination, axonal degeneration, andF-κB and JNK activation in T cells. (A-B) Jurkat T cells and (C)
r indicated time points. Where indicated, mepazine was added 90
BCL10 was analyzed via western blot (A), and lysates were analyzed
o-ERK and actin (B-C).
Figure 4 Peripheral splenocyte activation is inhibited in the presence of mepazine. Splenocytes from MOG peptide-immunized mice were
cultured and stimulated with the indicated concentrations of MOG peptide in the presence or absence of mepazine (n = 4 for each condition).
Culture supernatants were collected 48 h after MOG peptide stimulation and assayed for IL-2 (A), IFNγ (B) and IL-17 (C). Results are displayed as
mean ± SEM. *P <0.05, **P <0.01, ***P <0.001.
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result from the capacity of mepazine to reduce periph-
eral autoantigen-specific T cell responses. Similarly,
in vivo MOG-primed T cells induced a less severe dis-
ease course when donor mice were treated with mepa-
zine. Importantly, the EAE inhibitory effect of mepazine
was not only observed in a prophylactic setting, but also
in a therapeutic setting where mepazine clearly pro-
motes remission.Previous studies demonstrated that the complete ab-
sence of MALT1 in knockout mice leads to a severe de-
fect in the development of Foxp3+ Tregs [17], consistent
with the essential role of agonist-induced TCR signaling
in the expression of Foxp3 and the development of
Tregs [19]. Since Tregs have a crucial role in the immune
system by preventing autoimmunity [19], limiting immu-
nopathology, and maintaining immune homeostasis, a de-
crease in Tregs would be harmful in any therapeutic
Figure 5 MALT1 inhibition does not affect regulatory T cell (Treg) development. Quantification of the percentage CD3+ CD4+ Foxp3+ cells
at 24 days post-immunization (A) or at different time points after experimental autoimmune encephalomyelitis (EAE) induction (B). Percentage
CD3+ CD4+ Foxp3+ cells from control and MALT1 knockout mice are included in panel (A). (C) Differentiation of naïve T cells into CD4+ Foxp3+
T cells at different time points in vitro. Data are depicted as mean ± SEM.
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Interestingly, no difference in the number of Foxp3+ Tregs
could be found between vehicle-treated and mepazine-
treated mice, demonstrating that a balanced inhibition of
TCR signaling by specific inhibition of MALT1 proteolytic
activity, leaving its scaffolding function intact, does not
affect the development of Tregs and holds promise for the
treatment of autoimmune disease.
Mepazine belongs to the class of phenothiazines that
are known as first generation antipsychotics and have
been in clinical use for the treatment of psychiatric dis-
orders since the early 1950s [20]. Mepazine was inclinical use as an antipsychotic drug under the brand
name Pacatal, but two placebo control trials failed to
show significant antipsychotic responses in patients lead-
ing to market removal in the early 1960s [21]. However,
clinical investigations reported no severe adverse effects
of mepazine even after long-term treatment for several
months at concentrations between 100 to 800 mg q.i.d.
[22]. Taking into account that metabolism of phenothia-
zines in rodents is in general much faster than in
humans, these data indicate that mepazine does not
cause severe toxicity in humans at concentrations that
may be beneficial for MS treatment [23,24]. Certainly,
Figure 6 Treatment with mepazine attenuates experimental autoimmune encephalomyelitis (EAE) and promotes remission. (A) Clinical
scores of mepazine-treated (n = 14) or vehicle-treated (n = 30) mice after treatment starting when mice reach a clinical score of 2.0. Results are
obtained from two independent experiments and data are depicted as mean ± SEM. (B) Kaplan-Meier plot showing remission (clinical score ≤1.5)
after mepazine treatment from mice in figure A. *P <0.05, ***P <0.001.
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and humans will be required, but the general ability of
phenothiazines to cross the blood-brain barrier further
strengthens the concept that mepazine can directly act
at the site of the autoimmune lesion [25].
Antipsychotic action of phenothiazines relies on the
blockade of the dopamine receptors system, but several
reasons reveal that the protective effect of mepazine on
EAE is not dependent on the antipsychotic action. In
fact, mepazine only insignificantly affects dopamine re-
ceptors and this finding corresponds to its clinical inef-
fectiveness for the treatment of psychiatric disorders
[26]. Importantly, we show that EAE is significantly re-
duced in mice after adoptive transfer of splenocytes from
mepazine-treated animals, lending strong support to the
model that the compound is acting by inhibiting MALT1
in the autoreactive T cells. Further, from the class of
known phenothiazines mepazine is clearly the most ef-
fective MALT1 inhibitor [15], and the allosteric mode of
MALT1 inhibition has been confirmed by mutation ofthe mepazine binding site on MALT1 [16]. We cannot
exclude that other MALT1 independent processes may
contribute to the EAE protection, but the effective inhib-
ition of MALT1 in T cells, the impaired T cell responses,
the reduced CNS inflammation and the decreased dis-
ease incidence after adoptive splenocyte transfer from
mepazine-treated mice clearly point out that MALT1 is
the major target of mepazine in this animal model.
Conclusions
MALT1 targeting with mepazine and other small com-
pound inhibitors has recently been shown to hold sig-
nificant potential in the treatment of lymphoma. Our
studies now demonstrate the efficacy of MALT1 prote-
ase targeting in the treatment of autoimmune disease.
The present study illustrates its efficiency in a murine
model of MS and it will be interesting to study the effect
of MALT1 targeting in other inflammatory diseases such
as rheumatoid arthritis, psoriasis and inflammatory
bowel disease that involve increased T cell receptor
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may be available in the future, the previous clinical use
may facilitate a repurposing of mepazine and foster the
translation of our findings to the treatment of severe
autoimmune diseases in the clinic.
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